The strong performance of Elscint's CT product line paced thecompany to improved financial results for its second quarter (end-June).The Haifa vendor reported revenues for the quarter increasing21% to $66.1 million, compared to $54.7 million in the same
The strong performance of Elscint's CT product line paced thecompany to improved financial results for its second quarter (end-June).The Haifa vendor reported revenues for the quarter increasing21% to $66.1 million, compared to $54.7 million in the same perioda year ago.
The company's net income was up as well, to $4.9 million inthe most recent quarter, compared to $2.7 million in the secondquarter of 1995. Net income for the second quarter of 1995 includes$1.6 million from settlement of a patent dispute with Sopha Medical(SCAN 7/28/93).
Dr. Thomas Spackman, president of Elscint's U.S. subsidiary,said the numbers were paced by strong growth in internationalmarkets, as well as a good performance in CT both in the U.S.and globally.
"There has been a real resurgence in some of the markets,in Eastern and Western Europe, and to some extent North and SouthAmerica," Spackman said. "There is growth in rest ofthe world, and the U.S. is hanging on."
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.